Lupin
Lupin Limited, commonly referred to as Lupin, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1968, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Lupin is renowned for its diverse portfolio, which encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With a commitment to innovation, Lupin has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is particularly noted for its leadership in the anti-TB and cardiovascular segments, offering unique products that cater to unmet medical needs. As a result, Lupin has secured a competitive market position, consistently ranking among the top generic pharmaceutical companies globally.
DitchCarbon Score
How does Lupin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin's score of 27 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Lupin's reported carbon emissions
In 2023, Lupin's total carbon emissions amounted to approximately 410,755,000 kg CO2e, comprising 86,910,000 kg CO2e from Scope 1, 323,845,000 kg CO2e from Scope 2, and 854,936,000 kg CO2e from Scope 3 emissions. This represents a reduction from 2022, where total emissions were about 446,292,000 kg CO2e. Over the years, Lupin has demonstrated a commitment to reducing its carbon footprint. In 2021, the company reported total emissions of approximately 487,676,000 kg CO2e, which decreased to about 446,292,000 kg CO2e in 2022, and further down to 410,755,000 kg CO2e in 2023. This trend indicates a positive trajectory towards emission reduction. Lupin has not yet committed to a net-zero target but is actively engaged in near-term reduction initiatives. The company is classified under the Pharmaceuticals, Biotechnology, and Life Sciences sector and is based in India. While specific reduction targets have not been disclosed, Lupin's ongoing efforts reflect a commitment to addressing climate change and improving sustainability practices within its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lupin is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
